open access

Vol 3, No 1 (2000)
Published online: 2000-02-25
Submitted: 2012-01-23
Get Citation

Quantitative evidence of thyroid stunning in 131I cancer treatment

Hadjieva D. Tatiana
Nucl. Med. Rev 2000;3(1):47-51.

open access

Vol 3, No 1 (2000)
Published online: 2000-02-25
Submitted: 2012-01-23

Abstract

BACKGROUND: An obvious paradox remains in the diagnosis, treatment and follow-up of differentiated thyroid cancer by 131I. The higher the activity for raising diagnostic precision, the greater is the potential reduction in therapeutic effects. This is due to a phenomenon called thyroid stunning.
MATERIAL AND METHODS: 131I tracer and therapeutic parameters: uptake, effective half-life and thyroid remnants mass were compared in two different groups of patients. Pre-treatment planning of radioiodine (RI) ablation was performed in 30 patients after administration of 0,185-74 μBq. The same parameters comparison was performed in the second group of four cases. They received two or three single fractions of 600-2400 MBq 3-15 days apart (a long-term abandoned regime).
RESULTS: 1. Comparative data collected by pre-treatment planning and subsequent RI administration supported the thesis that low range tracer activity (0,7-74 μBq) does not cause thyroid stunning. We have registered higher or similar uptake in thyroid bed after 1100-3700 μbq in 90% of cases. Only in 10% of cases was therapeutic uptake lower than the tracer one. In 18% of patients the higher rate of uptake was associated with additional thyroid tissue visualized on the post-treatment scan. Half-life reduction only could be interpreted in the direction of stunning, but such changes characterizes every RI treatment, if it takes more than one administration. Data elucidate why our pre-treatment planning failed in one-third of the patients. 2. We have clearly observed thyroid stunning after 600-2400 MBq 131I. In one case only, even after 1200 MBq, stunning did not take place. Individual RI kinetics appear highly unpredictable. The author advocates avoiding high activity first pre-treatment scan in advanced cases with elevated thyroglobuline. It remains an unanswered question what time is necessary for stunning to recover.

Abstract

BACKGROUND: An obvious paradox remains in the diagnosis, treatment and follow-up of differentiated thyroid cancer by 131I. The higher the activity for raising diagnostic precision, the greater is the potential reduction in therapeutic effects. This is due to a phenomenon called thyroid stunning.
MATERIAL AND METHODS: 131I tracer and therapeutic parameters: uptake, effective half-life and thyroid remnants mass were compared in two different groups of patients. Pre-treatment planning of radioiodine (RI) ablation was performed in 30 patients after administration of 0,185-74 μBq. The same parameters comparison was performed in the second group of four cases. They received two or three single fractions of 600-2400 MBq 3-15 days apart (a long-term abandoned regime).
RESULTS: 1. Comparative data collected by pre-treatment planning and subsequent RI administration supported the thesis that low range tracer activity (0,7-74 μBq) does not cause thyroid stunning. We have registered higher or similar uptake in thyroid bed after 1100-3700 μbq in 90% of cases. Only in 10% of cases was therapeutic uptake lower than the tracer one. In 18% of patients the higher rate of uptake was associated with additional thyroid tissue visualized on the post-treatment scan. Half-life reduction only could be interpreted in the direction of stunning, but such changes characterizes every RI treatment, if it takes more than one administration. Data elucidate why our pre-treatment planning failed in one-third of the patients. 2. We have clearly observed thyroid stunning after 600-2400 MBq 131I. In one case only, even after 1200 MBq, stunning did not take place. Individual RI kinetics appear highly unpredictable. The author advocates avoiding high activity first pre-treatment scan in advanced cases with elevated thyroglobuline. It remains an unanswered question what time is necessary for stunning to recover.
Get Citation

Keywords

radioiodine tracer and treatment kinetics; thyroid stunning; pre-treatment planning

About this article
Title

Quantitative evidence of thyroid stunning in 131I cancer treatment

Journal

Nuclear Medicine Review

Issue

Vol 3, No 1 (2000)

Pages

47-51

Published online

2000-02-25

Bibliographic record

Nucl. Med. Rev 2000;3(1):47-51.

Keywords

radioiodine tracer and treatment kinetics
thyroid stunning
pre-treatment planning

Authors

Hadjieva D. Tatiana

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl